NDAINHALATION, ORALSOLUTIONPriority Review
Approved
Sep 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
MUCOMYST (acetylcysteine) by Bristol Myers Squibb is reduction activity [moa]. Approved for asthma. First approved in 1963.
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MUCOMYST (acetylcysteine) is a mucolytic agent that reduces mucus viscosity through reduction activity, administered via inhalation or oral routes. It is indicated for asthma and other respiratory conditions where mucus clearance is impaired. The drug works by breaking disulfide bonds in mucoproteins, facilitating expectoration.
LOE Approaching
Product approaching loss of exclusivity with low current competitive pressure (30/100), indicating limited growth opportunities and likely team contraction ahead.
Mechanism of Action
Reduction Activity
Indications (1)
Clinical Trials (20)
Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold
Started Sep 2024
0Common Cold
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label
Started Mar 2024
144 enrolled
Autism Spectrum Disorder
Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke
Started Nov 2023
4 enrolled
Acute Ischemic Stroke
Oral N-acetylcysteine for Retinitis Pigmentosa
Started Oct 2023
485 enrolled
Retinitis Pigmentosa
Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels
Started Jul 2023
18 enrolled
Mitochondrial Disease
Worked on MUCOMYST at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.